Select a State

Global health R&D delivers for Vermont

US government investment in global health R&D has delivered

$1.2 million
to Vermont research institutions

Neglected diseases in Vermont

Chikungunya cases
4
Dengue cases
19
HIV diagnoses
137
Malaria cases
29
Tuberculosis cases
48
West Nile cases
8
Zika cases
26

Vermont's top USG-funded global health R&D institutions

University of Vermont
$1.2 million

Vermont industry in global health R&D

Mylan
Location(s):
St. Albans City
QuantaSpec
Location(s):
Burlington, Essex Junction

Vermont's top areas of global health R&D by USG funding

19.5%
Malaria
80.5%
Diarrheal diseases

Global health R&D at work in Vermont

The University of Vermont’s Vaccine Testing Center is designing a research platform upon which new treatments for cryptosporidiosis can be tested in humans. Cryptosporidiosis, or crypto for short, is an infection caused by Cryptosporidium, a single-celled intestinal parasite found in soil, food, and water. Crypto is a leading cause of severe diarrhea in infants and young children in low-income countries. It also causes significant illness and death in immunocompromised individuals. No vaccines exist to treat or prevent the infection and there are limited treatment options. In many parts of the world, crypto is associated with poor childhood nutrition and stunted growth. Past work by the center has focused on how crypto contributes to the vicious cycle of diarrhea, infectious diseases, and malnutrition.

Footnotes